Research ExplorerPublicationsStrong expression of the neuronal transcription factor FOXP2...

Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.

Standard

Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers. / Stumm, Laura; Burkhardt, Lia; Steurer, Stefan; Simon, Ronald; Adam, Meike; Becker, Andreas; Sauter, Guido; Minner, Sarah; Schlomm, Thorsten; Sirma, Hüseyin; Michl, Uwe.

In: J CLIN PATHOL, Vol. 66, No. 7, 7, 2013, p. 563-568.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Stumm, L, Burkhardt, L, Steurer, S, Simon, R, Adam, M, Becker, A, Sauter, G, Minner, S, Schlomm, T, Sirma, H & Michl, U 2013, 'Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.', J CLIN PATHOL, vol. 66, no. 7, 7, pp. 563-568. https://doi.org/10.1136/jclinpath-2012-201335

APA

Stumm, L., Burkhardt, L., Steurer, S., Simon, R., Adam, M., Becker, A., Sauter, G., Minner, S., Schlomm, T., Sirma, H., & Michl, U. (2013). Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers. J CLIN PATHOL, 66(7), 563-568. [7]. https://doi.org/10.1136/jclinpath-2012-201335

Vancouver

Stumm L, Burkhardt L, Steurer S, Simon R, Adam M, Becker A et al. Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers. J CLIN PATHOL. 2013;66(7):563-568. 7. https://doi.org/10.1136/jclinpath-2012-201335

Bibtex

@article{3838260494214d94821dd2312f701fd9,
title = "Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.",
abstract = "BACKGROUND AND AIMS: Transcription factors of the forkhead box P (FOXP1-4) family have been implicated in various human cancer types before. The relevance and role of neuronal transcription factor FOXP2 in prostate cancer is unknown.METHODS: A tissue microarray containing samples from more than 11 000 prostate cancers from radical prostatectomy specimens with clinical follow-up data was analysed for FOXP2 expression by immunohistochemistry. FOXP2 data were also compared with pre-existing ERG fusion (by fluorescence in situ hybridisation and immunohistochemistry) and cell proliferation (Ki67 labelling index) data.RESULTS: There was a moderate to strong FOXP2 protein expression in basal and secretory cells of normal prostatic glands. As compared with normal cells, FOXP2 expression was lost or reduced in 25% of cancers. Strong FOXP2 expression was linked to advanced tumour stage, high Gleason score, presence of lymph node metastases and early tumour recurrence (p<0.0001; each) in ERG fusion-negative, but not in ERG fusion-positive cancers. High FOXP2 expression was linked to high Ki67 labelling index (p<0.0001) in all cancers irrespective of ERG fusion status.CONCLUSIONS: These data demonstrate that similar high FOXP2 protein levels as in normal prostate epithelium exert a 'paradoxical' oncogenic role in 'non fusion-type' prostate cancer. It may be speculated that interaction of FOXP2 with members of pathways that are specifically activated in 'non fusion-type' cancers may be responsible for this phenomenon.",
keywords = "Adenocarcinoma, Aged, Cell Proliferation, Forkhead Transcription Factors, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Ki-67 Antigen, Lymph Nodes, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Grading, Neoplasm Recurrence, Local, Oncogene Proteins, Fusion, Prostate, Prostate-Specific Antigen, Prostatic Neoplasms, Risk Factors, Tissue Array Analysis, Tumor Markers, Biological",
author = "Laura Stumm and Lia Burkhardt and Stefan Steurer and Ronald Simon and Meike Adam and Andreas Becker and Guido Sauter and Sarah Minner and Thorsten Schlomm and H{\"u}seyin Sirma and Uwe Michl",
year = "2013",
doi = "10.1136/jclinpath-2012-201335",
language = "English",
volume = "66",
pages = "563--568",
journal = "J CLIN PATHOL",
issn = "0021-9746",
publisher = "BMJ PUBLISHING GROUP",
number = "7",

}

RIS

TY - JOUR

T1 - Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.

AU - Stumm, Laura

AU - Burkhardt, Lia

AU - Steurer, Stefan

AU - Simon, Ronald

AU - Adam, Meike

AU - Becker, Andreas

AU - Sauter, Guido

AU - Minner, Sarah

AU - Schlomm, Thorsten

AU - Sirma, Hüseyin

AU - Michl, Uwe

PY - 2013

Y1 - 2013

N2 - BACKGROUND AND AIMS: Transcription factors of the forkhead box P (FOXP1-4) family have been implicated in various human cancer types before. The relevance and role of neuronal transcription factor FOXP2 in prostate cancer is unknown.METHODS: A tissue microarray containing samples from more than 11 000 prostate cancers from radical prostatectomy specimens with clinical follow-up data was analysed for FOXP2 expression by immunohistochemistry. FOXP2 data were also compared with pre-existing ERG fusion (by fluorescence in situ hybridisation and immunohistochemistry) and cell proliferation (Ki67 labelling index) data.RESULTS: There was a moderate to strong FOXP2 protein expression in basal and secretory cells of normal prostatic glands. As compared with normal cells, FOXP2 expression was lost or reduced in 25% of cancers. Strong FOXP2 expression was linked to advanced tumour stage, high Gleason score, presence of lymph node metastases and early tumour recurrence (p<0.0001; each) in ERG fusion-negative, but not in ERG fusion-positive cancers. High FOXP2 expression was linked to high Ki67 labelling index (p<0.0001) in all cancers irrespective of ERG fusion status.CONCLUSIONS: These data demonstrate that similar high FOXP2 protein levels as in normal prostate epithelium exert a 'paradoxical' oncogenic role in 'non fusion-type' prostate cancer. It may be speculated that interaction of FOXP2 with members of pathways that are specifically activated in 'non fusion-type' cancers may be responsible for this phenomenon.

AB - BACKGROUND AND AIMS: Transcription factors of the forkhead box P (FOXP1-4) family have been implicated in various human cancer types before. The relevance and role of neuronal transcription factor FOXP2 in prostate cancer is unknown.METHODS: A tissue microarray containing samples from more than 11 000 prostate cancers from radical prostatectomy specimens with clinical follow-up data was analysed for FOXP2 expression by immunohistochemistry. FOXP2 data were also compared with pre-existing ERG fusion (by fluorescence in situ hybridisation and immunohistochemistry) and cell proliferation (Ki67 labelling index) data.RESULTS: There was a moderate to strong FOXP2 protein expression in basal and secretory cells of normal prostatic glands. As compared with normal cells, FOXP2 expression was lost or reduced in 25% of cancers. Strong FOXP2 expression was linked to advanced tumour stage, high Gleason score, presence of lymph node metastases and early tumour recurrence (p<0.0001; each) in ERG fusion-negative, but not in ERG fusion-positive cancers. High FOXP2 expression was linked to high Ki67 labelling index (p<0.0001) in all cancers irrespective of ERG fusion status.CONCLUSIONS: These data demonstrate that similar high FOXP2 protein levels as in normal prostate epithelium exert a 'paradoxical' oncogenic role in 'non fusion-type' prostate cancer. It may be speculated that interaction of FOXP2 with members of pathways that are specifically activated in 'non fusion-type' cancers may be responsible for this phenomenon.

KW - Adenocarcinoma

KW - Aged

KW - Cell Proliferation

KW - Forkhead Transcription Factors

KW - Humans

KW - Immunohistochemistry

KW - In Situ Hybridization, Fluorescence

KW - Ki-67 Antigen

KW - Lymph Nodes

KW - Lymphatic Metastasis

KW - Male

KW - Middle Aged

KW - Neoplasm Grading

KW - Neoplasm Recurrence, Local

KW - Oncogene Proteins, Fusion

KW - Prostate

KW - Prostate-Specific Antigen

KW - Prostatic Neoplasms

KW - Risk Factors

KW - Tissue Array Analysis

KW - Tumor Markers, Biological

U2 - 10.1136/jclinpath-2012-201335

DO - 10.1136/jclinpath-2012-201335

M3 - SCORING: Journal article

C2 - 23559350

VL - 66

SP - 563

EP - 568

JO - J CLIN PATHOL

JF - J CLIN PATHOL

SN - 0021-9746

IS - 7

M1 - 7

ER -